State Street’s Mereo BioPharma MREO Stock Holding History

State Street’s Portfolio MREO Stock Details MREO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$44K	Buy	133,379 +2,736	+2%	+$1.17K	﹤0.01%	4147
2025 Q4	$54.4K	Sell	130,643 -2,058	-2%	-$3.92K	﹤0.01%	4139
2025 Q3	$273K	Buy	132,701 +87,759	+195%	+$162K	﹤0.01%	3817
2025 Q2	$122K	Sell	44,942 -717	-2%	-$1.73K	﹤0.01%	3942
2025 Q1	$103K	Sell	45,659 -1,426	-3%	-$4.03K	﹤0.01%	3973
2024 Q4	$165K	Sell	47,085 -476	-1%	-$1.87K	﹤0.01%	3891
2024 Q3	$195K	Buy	+47,561	New	+$197K	﹤0.01%	3829
2022 Q2	–	Sell	-412,768	Closed	-$458K	–	4960
2022 Q1	$458K	Hold	412,768	–	–	﹤0.01%	4088
2021 Q4	$660K	Hold	412,768	–	–	﹤0.01%	3917
2021 Q3	$1M	Buy	412,768 +334,568	+428%	+$886K	﹤0.01%	3781
2021 Q2	$248K	Buy	+78,200	New	+$262K	﹤0.01%	4132
2020 Q1	–	Sell	-16,516	Closed	-$54K	–	3780
2019 Q4	$54K	Hold	16,516	–	–	﹤0.01%	3718
2019 Q3	$48K	Hold	16,516	–	–	﹤0.01%	3723
2019 Q2	$40K	Buy	+16,516	New	+$72.2K	﹤0.01%	3734

Other funds holding MREO

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $712M AUM

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return

State Street's MREO Position: Q1 2026 in Review

State Street increased its Mereo BioPharma (MREO) stake by 2.1% in Q1 2026, buying an estimated $1.17K and bringing the position to 133,379 shares worth $44K. The position accounts for ﹤0.01% of the portfolio, ranked #4147.

State Street first reported a position in MREO in Q2 2019 and has held it in 14 quarters since. The position peaked at $1M in Q3 2021. 63 funds tracked by Wall St. Rank hold MREO as of Q1 2026.

State Street held 133,379 shares of Mereo BioPharma worth $44K as of Q1 2026.
State Street bought 2,736 Mereo BioPharma shares in Q1 2026, an estimated $1.17K.
Mereo BioPharma made up ﹤0.01% of State Street's portfolio in Q1 2026, its #4147 holding.
State Street first reported a position in Mereo BioPharma in Q2 2019 and has held it in 14 quarters since.
State Street's Mereo BioPharma position peaked at $1M in Q3 2021.
63 funds tracked by Wall St. Rank held Mereo BioPharma as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.